Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review


  1. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

    Publikation: Bidrag til tidsskriftTidsskriftartikel

  • Kausik K Ray
  • Bart Molemans
  • W Marieke Schoonen
  • Periklis Giovas
  • Sarah Bray
  • Gaia Kiru
  • Jennifer Murphy
  • Maciej Banach
  • Stefano De Servi
  • Dan Gaita
  • Ioanna Gouni-Berthold
  • G Kees Hovingh
  • Jacek J Jozwiak
  • J Wouter Jukema
  • Robert Gabor Kiss
  • Serge Kownator
  • Helle K Iversen
  • Vincent Maher
  • Luis Masana
  • Alexander Parkhomenko
  • André Peeters
  • Piers Clifford
  • Katarina Raslova
  • Peter Siostrzonek
  • Stefano Romeo
  • Dimitrios Tousoulis
  • Charalambos Vlachopoulos
  • Michal Vrablik
  • Alberico L Catapano
  • Neil R Poulter
  • DA VINCI study
Vis graf over relationer

AIMS: To provide contemporary data on the implementation of European guideline recommendations for lipid-lowering therapies (LLTs) across different settings and populations and how this impacts low-density lipoprotein cholesterol (LDL-C) goal achievement.

METHODS AND RESULTS: An 18 country, cross-sectional, observational study of patients prescribed LLT for primary or secondary prevention in primary or secondary care across Europe. Between June 2017 and November 2018, data were collected at a single visit, including LLT in the preceding 12 months and most recent LDL-C. Primary outcome was the achievement of risk-based 2016 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) LDL-C goal while receiving stabilized LLT; 2019 goal achievement was also assessed. Overall, 5888 patients (3000 primary and 2888 secondary prevention patients) were enrolled; 54% [95% confidence interval (CI) 52-56] achieved their risk-based 2016 goal and 33% (95% CI 32-35) achieved their risk-based 2019 goal. High-intensity statin monotherapy was used in 20% and 38% of very high-risk primary and secondary prevention patients, respectively. Corresponding 2016 goal attainment was 22% and 45% (17% and 22% for 2019 goals) for very high-risk primary and secondary prevention patients, respectively. Use of moderate-high-intensity statins in combination with ezetimibe (9%), or any LLT with PCSK9 inhibitors (1%), was low; corresponding 2016 and 2019 goal attainment was 53% and 20% (ezetimibe combination), and 67% and 58% (PCSK9i combination).

CONCLUSION: Gaps between clinical guidelines and clinical practice for lipid management across Europe persist, which will be exacerbated by the 2019 guidelines. Even with optimized statins, greater utilization of non-statin LLT is likely needed to reduce these gaps for patients at highest risk.

TidsskriftEuropean Journal of Preventive Cardiology
Udgave nummer11
Sider (fra-til)1279-1289
Antal sider11
StatusUdgivet - 1 nov. 2021

Bibliografisk note

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

ID: 62245741